menu

Rare Neurological Disease Treatment Market

Schedule Call

Rare Neurological Disease Treatment Market

Rare Neurological Disease Treatment Market by Drug Type (Biologics, Small Molecules), Indication (Narcolepsy, Creutzfeldt-Jakob Disease, Multiple Sclerosis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies)– Global Outlook & Forecast 2023-2031

GR - 735271 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: May 31, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


Rare Neurological Disease Treatment Market Scope

Report Attribute

Details

Market Size Value in 2022

US$ 8.67 billion

Revenue Forecast in 2031

US$ 13.02 billion

CAGR

8.2%

Base Year for Estimation

2022

Forecast Period

2023 to 2031

Historical Year

2021

Segments Covered

Drug Type, Indication, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the rare neurological disease treatment market was valued at US$ 8.67 billion in 2022 and is expected to register a revenue CAGR of 8.2% to reach US$ 13.02 billion by 2031.

Rare Neurological Disease Treatment Market Fundamentals 

A rare neurological disease is a neurological disorder that affects a relatively small number of people compared to more common neurological conditions. These diseases often have low prevalence rates, meaning they are uncommon in the general population. Less than 1 in 100,000 individuals are affected by rare neurological illnesses. Because it can enhance the quality of life for those who suffer from these disorders, treatment for rare neurological diseases is crucial. Pharmaceutical companies research and develop medications specifically targeted at managing symptoms or slowing the progression of rare neurological disorders. These treatments may involve the use of drugs, such as disease-modifying therapies, immunomodulators, or symptom-management medications. Gene therapy holds significant potential for treating rare neurological diseases caused by genetic mutations. It involves introducing genetic material into a patient's cells to correct or replace the faulty genes responsible for the condition.

Rare Neurological Disease Treatment Market Dynamics 

The global rare neurological disease treatment market has significant growth potential due to several key drivers that are fueling advancements and investment in this field. In terms of disease diagnosis, treatment, and management, uncommon neurological diseases place a major burden on healthcare systems. Narcolepsy, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others are among the most common uncommon neurological illnesses. 7,000 uncommon neurological disorders have been documented in the U.S., according to statistics from the National Institute of Neurological Disorders and Stroke published in 2019. Additionally, a large amount of morbidity and mortality are caused by these disorders, according to the same study. The major causes of an increase in the prevalence of rare neurological illnesses include sleep deprivation, psychological stress, an inherited genetic defect, abrupt changes in sleep patterns, and aging. These variables make the elderly more susceptible to neurological ailments.

Additionally, these illnesses increase morbidity and disability, which impacts the country's economy. As the world's population ages, there will likely be an increase in neurological sleep-related illnesses in the years to come. Around 40 million Americans suffer from neurological illnesses, and another 20 million occasionally have sleeping issues, according to data from the National Institutes of Health (NIH) published in 2019. Precision medicine, which focuses on tailoring treatments to an individual's specific genetic, molecular, and clinical characteristics, has revolutionized healthcare. The understanding of rare neurological diseases at a molecular level has increased, enabling the development of targeted therapies. Advances in genomics, proteomics, and biomarker identification have paved the way for personalized treatment approaches that address the underlying causes of these diseases. These growth drivers provide a favorable environment for research, development, and investment in the treatment market for rare neurological diseases.

However, rare neurological diseases affect a small number of individuals. Due to the potential lack of profitability, the limited patient population makes it financially challenging for pharmaceutical companies to invest in research and treatment development. This limitation often leads to a scarcity of funding and resources for developing therapies for these diseases. The market for treatments for rare neurological diseases is also anticipated to grow slowly due to the high cost of those treatments.

Rare Neurological Disease Treatment Market Ecosystem

The global rare neurological disease treatment market is analyzed from the following perspectives: drug type, indication, distribution channel, and region. 

Rare Neurological Disease Treatment Market by Drug Type

Based on the drug type, the global rare neurological disease treatment market is segmented into biologics and small molecules.

Small molecules account for the largest revenue share in the global rare neurological disease treatment market. A small molecule is a drug that can enter cells quickly due to its low molecular weight. The segment is dominating due to the higher cost of biological drugs. Small molecules can be utilized to treat genetic epilepsies, including uncommon or ultrarare genetic epilepsy, according to a study report published in August 2021 in the Neurotherapeutics Journal. Small compounds have the benefit of being able to access extracellular and intracellular targets, allowing for the control of specific protein activities like ion channel gating. Additionally, these chemicals can be produced more rapidly, in greater quantities, and at a lower cost, making them advantageous for the future development of medications for uncommon diseases. Such investigations will likely open up new possibilities and boost demand for small molecules in treating uncommon neurological illnesses.

Rare Neurological Disease Treatment Market by Indication

Based on the indication, the global rare neurological disease treatment market is segmented into narcolepsy, Creutzfeldt-Jakob disease, multiple sclerosis, spinal muscular atrophy, and others.

Creutzfeldt-Jakob disease (CJD) segment held a significant revenue share in the global rare neurological disease treatment market. CJD is a rare and fatal degenerative neurological disorder. CJD is the most common form, accounting for about 85% of cases. The estimated annual incidence of CJD varies geographically, ranging from about 0.5 to 1.5 cases per million population.

Rare Neurological Disease Treatment Market by Distribution Channel

Based on the distribution channel, the global rare neurological disease treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Hospital pharmacies account for the largest revenue share of over 65% of the global rare neurological disease treatment market. This is because hospitals have access to many different medications for treating neurological problems. Additionally, hospital-based pharmaceutical firms are working on research projects to create new treatments that will be less likely to cause adverse effects than previous medications. Due to expanding public awareness of health and safety issues and an increase in the prevalence of rare neurological diseases like Parkinson's disease and Alzheimer's disease worldwide, retail pharmacies are predicted to have the fastest growth during the forecast period.

Rare Neurological Disease Treatment Market by Region

Geographically, the global rare neurological disease treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America accounts for a significant revenue share in the rare neurological disease treatment market. This is because reimbursement is available for treating uncommon diseases, the prevalence of rare neurological disorders is rising, and regional research and development (R&D) is growing. According to a StatPearls article updated in March 2022, about 350 instances of Creutzfeldt-Jakob disease (CJD) are diagnosed each year in the United States, which is consistent with an Orphanet report released in January 2022. The most prevalent type of human prion disease is sporadic CJD, with a mean age of onset of 61 years. Therefore, throughout the forecast period, the high prevalence in the region is anticipated to fuel demand for the market for treating uncommon neurological diseases.

Additionally, the strategic actions taken by market participants, such as product launches, approvals, collaborations, and partnerships, support the expansion of the market under investigation. For instance, the US FDA granted Novartis Fast Track status in December 2021 for branaplam (LMI070), a medication used to treat HD. During the forecast period, product launches and approvals are anticipated to fuel the market in the area. Rising healthcare R&D spending and the availability of established healthcare infrastructure are other major contributors to the regional market's growth. For instance, according to the National Institutes of Health (NIH) RePORT 2022 report, the amount spent on research into Huntington's disease in 2020 and 2021 was 49 and 46 million dollars, respectively. In the United States, R&D expenditures on Huntington's disease are projected to total USD 48 million in 2022.

Due to the large unmet clinical needs, quickly developing healthcare infrastructure, and economic development, particularly in India, China, Japan, Singapore, and South Korea, Asia Pacific is anticipated to grow at the quickest rate throughout the projection period.

Rare Neurological Disease Treatment Market Competitive Landscape

The prominent players operating in the global rare neurological disease treatment marketare: -

  • Bayer AG
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co. Inc.
  • CSL Ltd.
  • Kedrion Biopharma Inc.
  • US WorldMeds LLC (Solstice Neurosciences LLC)
  • Aquestive Therapeutics Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Allergan Plc

Rare Neurological Disease Treatment Market Strategic Developments

  • In September 2021, a gene therapy partnership between NeuExcell Therapeutics and Spark Therapeutics was established to create a secure and efficient treatment for those who have HD.
  • In July 2021, In India, Roche introduced Evrysdi, a prescription drug intended to treat spinal muscular atrophy in adults and children two months of age and older.

Frequently Asked Questions About This Report

A rare neurological disease is a neurological disorder that affects a relatively small number of people compared to more common neurological conditions.

The global rare neurological disease treatment market during the forecast period is expected to grow at a revenue CAGR of 8.2%.

Bayer AG, Pfizer Inc., Novartis AG, Merck & Co. Inc., and CSL Ltd. are the major players in the rare neurological disease treatment market.

The Asia Pacific region is projected to grow at a high revenue CAGR in the global rare neurological disease treatment market.

Due to the high costs associated with developing treatments for rare diseases, the reimbursement landscape can present challenges.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022)
    3. Regulatory Landscape
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3.  Opportunities
  5. GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET - ANALYSIS & FORECAST, BY DRUG TYPE
    1. Biologics
    2. Small Molecules
  6. GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET - ANALYSIS & FORECAST, BY INDICATION
    1. Narcolepsy
    2. Creutzfeldt-Jakob Disease
    3. Multiple Sclerosis
    4. Spinal Muscular Atrophy
    5. Others
  7. GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies
    2. Retail Pharmacies 
    3. Online Pharmacies
  8. GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Rare Neurological Disease Treatment Market
      1. North America Rare Neurological Disease Treatment Market, by Drug Type
      2. North America Rare Neurological Disease Treatment Market, by Indication
      3. North America Rare Neurological Disease Treatment Market, by Distribution Channel
      4. North America Rare Neurological Disease Treatment Market, by Country
        1. U.S.
          1. U.S. Rare Neurological Disease Treatment Market, by Drug Type
          2. U.S. Rare Neurological Disease Treatment Market, by Indication
          3. U.S. Rare Neurological Disease Treatment Market, by Distribution Channel
        2. Canada
          1. Canada Rare Neurological Disease Treatment Market, by Drug Type
          2. Canada Rare Neurological Disease Treatment Market, by Indication
          3. Canada Rare Neurological Disease Treatment Market, by Distribution Channel
    2. Europe Rare Neurological Disease Treatment Market
      1. Europe Rare Neurological Disease Treatment Market, by Drug Type
      2. Europe Rare Neurological Disease Treatment Market, by Indication
      3. Europe Rare Neurological Disease Treatment Market, by Distribution Channel
      4. Europe Rare Neurological Disease Treatment Market, by Country/Region
        1. Germany
          1. Germany Rare Neurological Disease Treatment Market, by Drug Type
          2. Germany Rare Neurological Disease Treatment Market, by Indication
          3. Germany Rare Neurological Disease Treatment Market, by Distribution Channel
        2. U.K.
          1. U.K. Rare Neurological Disease Treatment Market, by Drug Type
          2. U.K. Rare Neurological Disease Treatment Market, by Indication
          3. U.K. Rare Neurological Disease Treatment Market, by Distribution Channel
        3. France
          1. France Rare Neurological Disease Treatment Market, by Drug Type
          2. France Rare Neurological Disease Treatment Market, by Indication
          3. France Rare Neurological Disease Treatment Market, by Distribution Channel
        4. Spain
          1. Spain Rare Neurological Disease Treatment Market, by Drug Type
          2. Spain Rare Neurological Disease Treatment Market, by Indication
          3. Spain Rare Neurological Disease Treatment Market, by Distribution Channel
        5. Italy
          1. Italy Rare Neurological Disease Treatment Market, by Drug Type
          2. Italy Rare Neurological Disease Treatment Market, by Indication
          3. Italy Rare Neurological Disease Treatment Market, by Distribution Channel
        6. Rest of Europe 
          1. Rest of Europe Rare Neurological Disease Treatment Market, by Drug Type
          2. Rest of Europe Rare Neurological Disease Treatment Market, by Indication
          3. Rest of Europe Rare Neurological Disease Treatment Market, by Distribution Channel
    3. Asia Pacific Rare Neurological Disease Treatment Market
      1. Asia Pacific Rare Neurological Disease Treatment Market, by Drug Type
      2. Asia Pacific Rare Neurological Disease Treatment Market, by Indication
      3. Asia Pacific Rare Neurological Disease Treatment Market, by Distribution Channel
      4. Asia Pacific Rare Neurological Disease Treatment Market, by Country/Region
        1. China
          1. China Rare Neurological Disease Treatment Market, by Drug Type
          2. China Rare Neurological Disease Treatment Market, by Indication
          3. China Rare Neurological Disease Treatment Market, by Distribution Channel
        2. Japan
          1. Japan Rare Neurological Disease Treatment Market, by Drug Type
          2. Japan Rare Neurological Disease Treatment Market, by Indication
          3. Japan Rare Neurological Disease Treatment Market, by Distribution Channel
        3. India
          1. India Rare Neurological Disease Treatment Market, by Drug Type
          2. India Rare Neurological Disease Treatment Market, by Indication
          3. India Rare Neurological Disease Treatment Market, by Distribution Channel
        4. South Korea
          1. South Korea Rare Neurological Disease Treatment Market, by Drug Type
          2. South Korea Rare Neurological Disease Treatment Market, by Indication
          3. South Korea Rare Neurological Disease Treatment Market, by Distribution Channel
        5. Australia
          1. Australia Rare Neurological Disease Treatment Market, by Drug Type
          2. Australia Rare Neurological Disease Treatment Market, by Indication
          3. Australia Rare Neurological Disease Treatment Market, by Distribution Channel
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Rare Neurological Disease Treatment Market, by Drug Type
          2. Rest of Asia Pacific Rare Neurological Disease Treatment Market, by Indication
          3. Rest of Asia Pacific Rare Neurological Disease Treatment Market, by Distribution Channel
    4. Latin America Rare Neurological Disease Treatment Market
      1. Latin America Rare Neurological Disease Treatment Market, by Drug Type
      2. Latin America Rare Neurological Disease Treatment Market, by Indication
      3. Latin America Rare Neurological Disease Treatment Market, by Distribution Channel
      4. Latin America Rare Neurological Disease Treatment Market, by Country/Region
        1. Brazil 
          1. Brazil Rare Neurological Disease Treatment Market, by Drug Type
          2. Brazil Rare Neurological Disease Treatment Market, by Indication
          3. Brazil Rare Neurological Disease Treatment Market, by Distribution Channel
        2. Mexico 
          1. Mexico Rare Neurological Disease Treatment Market, by Drug Type
          2. Mexico Rare Neurological Disease Treatment Market, by Indication
          3. Mexico Rare Neurological Disease Treatment Market, by Distribution Channel
        3. Argentina 
          1. Argentina Rare Neurological Disease Treatment Market, by Drug Type
          2. Argentina Rare Neurological Disease Treatment Market, by Indication
          3. Argentina Rare Neurological Disease Treatment Market, by Distribution Channel
        4. Rest of Latin America 
          1. Rest of Latin America Rare Neurological Disease Treatment Market, by Drug Type
          2. Rest of Latin America Rare Neurological Disease Treatment Market, by Indication
          3. Rest of Latin America Rare Neurological Disease Treatment Market, by Distribution Channel
    5. Middle East & Africa Rare Neurological Disease Treatment Market
      1. Middle East & Africa Rare Neurological Disease Treatment Market, by Drug Type
      2. Middle East & Africa Rare Neurological Disease Treatment Market, by Indication
      3. Middle East & Africa Rare Neurological Disease Treatment Market, by Distribution Channel
      4. Middle East & Africa Rare Neurological Disease Treatment Market, by Country/Region 
        1. GCC Countries 
          1. GCC Countries Rare Neurological Disease Treatment Market, by Drug Type
          2. GCC Countries Rare Neurological Disease Treatment Market, by Indication
          3. GCC Countries Rare Neurological Disease Treatment Market, by Distribution Channel
        2. South Africa
          1. South Africa Rare Neurological Disease Treatment Market, by Drug Type
          2. South Africa Rare Neurological Disease Treatment Market, by Indication
          3. South Africa Rare Neurological Disease Treatment Market, by Distribution Channel
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Rare Neurological Disease Treatment Market, by Drug Type
          2. Rest of Middle East & Africa Rare Neurological Disease Treatment Market, by Indication
          3. Rest of Middle East & Africa Rare Neurological Disease Treatment Market, by Distribution Channel
  9. COMPANY PROFILE
    1. Bayer AG
      1. Business Snapshot 
      2. Products Offered 
      3. Financial Details 
      4. Strategic Development
    2. Pfizer Inc.
    3. Novartis AG
    4. Merck & Co. Inc.
    5. CSL Ltd.
    6. Kedrion Biopharma Inc.
    7. US WorldMeds LLC (Solstice Neurosciences LLC)
    8. Aquestive Therapeutics Inc.
    9. Merz Pharma GmbH & Co. KGaA
    10. Allergan Plc

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million)
  2. Global Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  3. Global Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  4. Global Rare Neurological Disease Treatment Market, by Region, 2021-2031 (US$ Million) 
  5. North America Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million)
  6. North America Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  7. North America Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  8. North America Rare Neurological Disease Treatment Market, By Country, 2021-2031 (US$ Million) 
  9. U.S. Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  10. U.S. Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  11. U.S. Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  12. Canada Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million)
  13. Canada Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  14. Canada Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  15. Europe Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  16. Europe Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  17. Europe Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  18. Europe Rare Neurological Disease Treatment Market, By Country/ Region, 2021-2031 (US$ Million) 
  19. Germany Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  20. Germany Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  21. Germany Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  22. U.K. Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  23. U.K. Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  24. U.K. Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  25. France Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  26. France Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  27. France Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  28. Italy Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  29. Italy Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  30. Italy Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  31. Spain Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  32. Spain Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  33. Spain Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  34. Rest of Europe Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  35. Rest of Europe Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  36. Rest of Europe Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  37. Asia Pacific Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  38. Asia Pacific Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  39. Asia Pacific Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  40. Asia Pacific Rare Neurological Disease Treatment Market, By Country/ Region, 2021-2031 (US$ Million) 
  41. China Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million)
  42. China Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  43. China Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  44. Japan Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  45. Japan Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  46. Japan Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  47. India Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  48. India Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  49. India Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  50. South Korea Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  51. South Korea Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  52. South Korea Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  53. Australia Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  54. Australia Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  55. Australia Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  56. Rest of Asia Pacific Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  57. Rest of Asia Pacific Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  58. Rest of Asia Pacific Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  59. Latin America Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  60. Latin America Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  61. Latin America Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  62. Latin America Rare Neurological Disease Treatment Market, by Country/Region, 2021-2031 (US$ Million)
  63. Brazil Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  64. Brazil Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  65. Brazil Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  66. Mexico Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  67. Mexico Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  68. Mexico Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  69. Argentina Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  70. Argentina Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  71. Argentina Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  72. Rest of Latin America Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  73. Rest of Latin America Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  74. Rest of Latin America Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  75. Middle East & Africa Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  76. Middle East &Africa Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  77. Middle East and Africa Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  78. Middle East and Africa Rare Neurological Disease Treatment Market, by Country/Region, 2021-2031 (US$ Million)
  79. GCC Countries Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  80. GCC Countries Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  81. GCC Countries Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  82. South Africa Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  83. South Africa Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  84. South Africa Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)
  85. Rest of Middle East and Africa Rare Neurological Disease Treatment Market, by Drug Type, 2021-2031 (US$ Million) 
  86. Rest of Middle East and Africa Rare Neurological Disease Treatment Market, by Indication, 2021-2031 (US$ Million)
  87. Rest of Middle East and Africa Rare Neurological Disease Treatment Market, by Distribution Channel, 2021-2031 (US$ Million)

List of Figures

 

  1. Rare Neurological Disease Treatment Market Ecosystem  
  2. Snapshot of Global Rare Neurological Disease Treatment Market, 2021 & 2031 
  3. Snapshot of Global Rare Neurological Disease Treatment Market, By Region, 2021 & 2031
  4. Global Rare Neurological Disease Treatment Market: COVID-19 Pandemic Impact Assessment
  5. Global Rare Neurological Disease Treatment Market: Key Players & Competitive Positioning (2022) 
  6. Rare Neurological Disease Treatment: Market Dynamics 
  7. Global Rare Neurological Disease Treatment Market for Biologics, 2021-2031 (US$ Million) 
  8. Global Rare Neurological Disease Treatment Market for Small Molecules, 2021-2031 (US$ Million) 
  9. Global Rare Neurological Disease Treatment Market for Narcolepsy, 2021-2031 (US$ Million)  
  10. Global Rare Neurological Disease Treatment Market for Creutzfeldt-Jakob Disease, 2021-2031 (US$ Million)
  11. Global Rare Neurological Disease Treatment Market for Multiple Sclerosis, 2021-2031 (US$ Million) 
  12. Global Rare Neurological Disease Treatment Market for Spinal Muscular Atrophy, 2021-2031 (US$ Million)
  13. Global Rare Neurological Disease Treatment Market for Others, 2021-2031 (US$ Million)
  14. Global Rare Neurological Disease Treatment Market for Hospital Pharmacies, 2021-2031 (US$ Million)
  15. Global Rare Neurological Disease Treatment Market for Retail Pharmacies, 2021-2031 (US$ Million)
  16. Global Rare Neurological Disease Treatment Market for Online Pharmacies, 2021-2031 (US$ Million)
  17. North America Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  18. U.S. Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  19. Canada Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  20. Europe Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  21. Germany Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  22. U.K. Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  23. France Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  24. Italy Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  25. Spain Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  26. Rest of Europe Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  27. Asia Pacific Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  28. China Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  29. Japan Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  30. India Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  31. South Korea Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  32. Australia Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  33. Rest of Asia Pacific Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  34. Latin America Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  35. Brazil Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  36. Mexico Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  37. Argentina Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  38. Rest of Latin America Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  39. Middle East & Africa Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  40. GCC Countries Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  41. South Africa Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million) 
  42. Rest of Middle East & Africa Rare Neurological Disease Treatment Market, 2021-2031 (US$ Million)
  43. Bayer AG Revenue from 2019 Onwards (US$ Million)
  44. Pfizer Inc. Revenue from 2019 Onwards (US$ Million)
  45. Novartis AG Revenue from 2019 Onwards (US$ Million)
  46. Merck & Co. Inc. Revenue from 2019 Onwards (US$ Million)
  47. CSL Ltd. Revenue from 2019 Onwards (US$ Million)
  48. Kedrion Biopharma Inc. Revenue from 2019 Onwards (US$ Million)
  49. US WorldMeds LLC (Solstice Neurosciences LLC) Revenue from 2019 Onwards (US$ Million)
  50. Aquestive Therapeutics Inc. Revenue from 2019 Onwards (US$ Million)
  51. Merz Pharma GmbH & Co. KGaA Revenue from 2019 Onwards (US$ Million)
  52. Allergan Plc Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Rare Neurological Disease Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Rare Neurological Disease Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports